HVIVO Seeks Big Pharma Partner For ‘Phase III-Ready’ Universal Flu Vaccine
Executive Summary
Presenting Phase IIb data on FLU-v, specialized CRO hVIVO now hopes to secure a big pharma partner for Phase III studies and commercialization of the universal flu vaccine candidate. The product has been developed in a joint venture with SEEK.
You may also be interested in...
Doubling Up On Vaccines: A Combined Zika And Dengue Vaccine May Be Possible
The global research effort to halt the spread of Zika virus now includes candidate vaccines from the US NIH, Takeda and Moderna Therapeutics.
Can Synthetic Vaccines Change The World’s Approach To Infectious Disease Crises?
Emerging Company Profile: Emergex Vaccines will use its nanobody technology to develop entirely synthetic immunizations against the world’s most concerning infectious diseases, including Ebola; evolving current options for vaccine stockpiling and national repositories.
Vaccitech Will Seek Partners For Its Universal Flu Vaccine
Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.